Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
- Resource Type
- Article
- Source
- In
The Lancet Gastroenterology & Hepatology September 2020 5(9):819-828 - Subject
Primary Research Articles - Language
- ISSN
- 2468-1253